-
公开(公告)号：US09604965B2
公开(公告)日：2017-03-28
申请号：US14594274
申请日：2015-01-12
Applicant: Cytokinetics, Inc.
Inventor： Luke W. Ashcraft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R. Muci , Xiangping Qian , Jeffrey Warrington , Zhe Yang , Pu-Ping Lu , Antonio Romero
IPC: A61K31/50 , C07D237/20 , C07D401/12 , C07D237/24 , C07D401/04 , C07D403/04 , C07D403/06 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , C07D401/14 , C07D405/14
CPC classification number: A61K31/50 , A61K31/16 , A61K31/166 , C07D207/26 , C07D211/76 , C07D213/16 , C07D231/56 , C07D237/06 , C07D237/20 , C07D237/24 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/14 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , Y02A50/465
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20230083960A1
公开(公告)日：2023-03-16
申请号：US17453761
申请日：2021-11-05
Applicant: Cytokinetics, Inc.
Inventor： Bradley P. MORGAN , Chris Evans , Pu-Ping Lu , Makoto Yamasaki , Wenyue Wang , Scott Collibee , Takuya Makino , Kazuyuki Tsuchiya , Toshio Kurosaki , Susumu Yamaki , Eriko Honjo , Yuka Koizumi , Naoto Katoh , Ryuichi Sekioka , Ikumi Kuriwaki , Denise Andersen
IPC: C07D243/14 , C07D471/04 , C07D487/04 , C07D498/04 , C07D405/14 , C07D401/12 , C07D403/14 , C07D519/00 , C07D413/12 , C07D471/10 , C07D417/12 , C07D413/08
Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein.
Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.-
公开(公告)号：US20210198203A1
公开(公告)日：2021-07-01
申请号：US17200174
申请日：2021-03-12
Applicant: CYTOKINETICS, INC.
Inventor： Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, JR.
IPC: C07D213/75 , C07D211/56 , C07D239/42 , C07D261/14 , C07D263/48 , C07D271/113 , C07D295/26 , C07D401/10 , C07D401/12 , C07D417/10 , C07D487/04 , C07D491/04 , C07D513/04 , C07D417/00 , C07D417/12
Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
公开(公告)号：US10765624B2
公开(公告)日：2020-09-08
申请号：US16352626
申请日：2019-03-13
Applicant: Cytokinetics, Inc.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: A61K9/00 , C07D403/04 , C07D239/42 , C07D513/04 , C07D495/04 , C07D471/04 , C07D417/04 , C07D413/14 , C07D409/14 , C07D401/14 , C07D401/12 , C07D239/48 , C07D403/10 , C07D401/04 , C07D417/14
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10272030B2
公开(公告)日：2019-04-30
申请号：US15645977
申请日：2017-07-10
Applicant: CYTOKINETICS, INC.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: A61K9/00 , C07D513/04 , C07D471/04 , C07D417/14 , C07D413/14 , C07D409/14 , C07D403/10 , C07D403/04 , C07D401/14 , C07D401/12 , C07D401/04 , C07D239/48 , C07D239/42 , C07D495/04
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
公开(公告)号：US09730886B2
公开(公告)日：2017-08-15
申请号：US14594315
申请日：2015-01-12
Applicant: Cytokinetics, Inc.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: C07D403/04 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D239/42 , C07D409/14 , C07D513/04 , C07D495/04 , A61K9/00 , C07D239/48 , C07D401/12 , C07D471/04 , C07D403/10
CPC classification number: A61K9/0014 , A61K9/0019 , A61K9/0034 , A61K9/0043 , A61K9/0048 , A61K9/0053 , A61K9/006 , A61K9/007 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11369565B2
公开(公告)日：2022-06-28
申请号：US16941079
申请日：2020-07-28
Applicant: Cytokinetics, Inc.
Inventor： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC: A61K9/14 , A61K9/00 , C07D403/04 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04 , C07D401/14 , C07D403/10
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.
Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US10076519B2
公开(公告)日：2018-09-18
申请号：US15463288
申请日：2017-03-20
Applicant: CYTOKINETICS, INC.
Inventor： Luke W. Ashcraft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R. Muci , Xiangping Qian , Jeffrey Warrington , Zhe Yang , Pu-Ping Lu , Antonio Romero
IPC: A61K31/501 , C07D403/02 , A61K31/50 , C07D237/06 , C07D231/56 , A61K31/16 , A61K31/166 , C07D213/16 , C07D207/26 , C07D211/76
CPC classification number: A61K31/50 , A61K31/16 , A61K31/166 , C07D207/26 , C07D211/76 , C07D213/16 , C07D231/56 , C07D237/06 , C07D237/20 , C07D237/24 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/14 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , Y02A50/465
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US08871768B2
公开(公告)日：2014-10-28
申请号：US13897086
申请日：2013-05-17
Applicant: Cytokinetics, Inc.
Inventor： Bradley P. Morgan , David J. Morgans , Alex Muci , Pu-Ping Lu , Erica A. Kraynack , Todd Tochimoto
IPC: A61K31/497 , A61K31/5377 , A61K31/4965 , A61K31/496 , C07D213/75
CPC classification number: C07D213/75 , A61K31/496 , A61K31/4965 , A61K31/497 , A61K31/5377
Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Abstract translation: 某些取代的脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。
-
公开(公告)号：US20190352267A1
公开(公告)日：2019-11-21
申请号：US16459754
申请日：2019-07-02
Applicant: CYTOKINETICS, INC.
Inventor： Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, JR.
IPC: C07D213/75 , C07D417/00 , C07D417/12 , C07D513/04 , C07D491/04 , C07D487/04 , C07D417/10 , C07D211/56 , C07D401/10 , C07D295/26 , C07D271/113 , C07D263/48 , C07D261/14 , C07D239/42 , C07D401/12
Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.022 seconds)
